CJC-1295, Hexarelin 10mg (Blend)

Hexarelin,which is a potent stimulator of the growth hormone secretagogue receptor. When combined with CJC-1295, a growth hormone releasing hormone receptor agonist, the two GH stimulants boost both baseline and peak levels of GH in animal models.

Both peptides have positive effects on cardiac (heart) muscle. Hexarelin, in particular, has been heavily investigated for its ability to protect heart cells from damage during ischemic injury (e.g. heart attack). There is good reason to believe that a combination of both peptides could improve outcomes during acute coronary events, aid recovery following myocardial injury, and even prevent cardiac injury in the first p^[1]–[3].

Hexarelin and CJC-1295 both potentiate fat metabolism and have been linked to improved measures of insulin resistance. Reduction in adipose tissue mass is linked to decreased systemic inflammation and improvements in everything from type 2 diabetes to the risk of developing cancer^[4]. Both peptides are also being investigated for their ability to protect muscle from the effects of chemotherapy^{[5], [6]}.

The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Aline Moulin’s research while affiliated with French National Centre for Scientific Research and other places are extensive. She is well versed in pharmaceutical development, management, external manufacturing operations, quality control, regulatory control, drug delivery, and drug discovery research. She has used Hexarelin in multiple studies to monitor if certain pharmaceuticals were capable of inhibiting many of its effects.

Aline Moulin's is being referenced as one of the leading scientists involved in the research and development of Hexarelin. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Aline Moulin is listed in [8] under the referenced citations.

1. X. Zhang, L. Qu, L. Chen, and C. Chen, “Improvement of cardiomyocyte function by in vivo hexarelin treatment in streptozotocin-induced diabetic rats,” Physiol. Rep., vol. 6, no. 4, 2018. [PubMed]
2. J. Huang, Y. Li, J. Zhang, Y. Liu, and Q. Lu, “The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway,” Int. Heart. J., vol. 58, no. 2, pp. 257–263, Apr. 2017. [PubMed]
3. Y. Ma, L. Zhang, J. N. Edwards, B. S. Launikonis, and C. Chen, “Growth hormone secretagogues protect mouse cardiomyocytes from in vitro ischemia/reperfusion injury through regulation of intracellular calcium,” PloS One, vol. 7, no. 4, p. e35265, 2012.
4. R. Mosa et al., “Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice,” Endocrinology, vol. 158, no. 10, pp. 3174–3187, 01 2017. [PubMed]
5. E. Conte et al., “Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia,” J. Cachexia Sarcopenia Muscle, vol. 8, no. 3, pp. 386–404, Jun. 2017. [PubMed]
6. G. Sirago et al., “Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia,” Sci. Rep., vol. 7, Oct. 2017. [Nature]
7.  X. Zhang, L. Qu, L. Chen, and C. Chen, “Improvement of cardiomyocyte function by in vivo hexarelin treatment in streptozotocin-induced diabetic rats,” Physiol. Rep., vol. 6, no. 4, 2018. [PubMed]
8.  Torsello, Antonio & Bresciani, Elena & Tamiazzo, Laura & Bulgarelli, Ilaria & Caporali, Simona & Moulin, Aline & Fehrentz, jean-alain & Martinez, Jean & Perissoud, Daniel & Locatelli, Vittorio. (2008). Novel potent and selective non-peptide ligands of ghrelin receptor : characterization of endocrine and extraendocrine actions. [Research Gate]

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body.  These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.  Bodily introduction of any kind into humans or animals is strictly forbidden by law.